Virginia Oncology Associates Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2008
NCT00661492
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Virginia Oncology Associates/US Oncology

Active Ingredients

Drugs in Phase 2 Trials (3)

cetuximab (erbitux) (1 trial)

mitoxantrone (novantrone) (1 trial)

tw1025 (1 trial)

Drugs in Phase 1 Trials (1)

xmt-1001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Fatigue (Phase 2)

Lung Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4